Foghorn reports Q3 2022 net loss $25.8M; FDA places FHD-286 AML/MDS trial on full clinical hold

Foghorn Therapeutics Inc.

Cash $373.5M as of Sep 30, 2022; runway into 2025.
FDA full clinical hold on FHD-286 AML/MDS study due to fatal differentiation syndrome; hold to be resolved.
FHD-286 mUM dose escalation continues; initial data expected H1 2023.
FHD-609 shows BRD9 degradation in synovial sarcoma biopsies; efficacy/safety data expected 2023.
New selective CBP degrader program disclosed; Merck collaboration triggered $5M milestone payment.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Foghorn Therapeutics Inc. reported quarter ended September 30, 2022 results: revenue $6.6 million.

Period: quarter ended September 30, 2022
Revenue: $6.6 million
Result: reported results

Exact text from the filing

Collaboration revenues were $6.6 million for the third quarter of 2022 compared to $0.1 million for the third quarter of 2021.

View on SEC.gov

Browse all earnings releases →

Foghorn Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001628280-22-028753

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.